1401863-92-0

Basic information

• Product Name: N-(4-aminobutyl)-1-(4-methoxyphenyl)-9H-β-carboline-3-amide
• Synonyms: N-(4-aminobutyl)-1-(4-methoxyphenyl)-9H-β-carboline-3-amide
• CAS NO: 1401863-92-0
• Molecular Weight: 388.469
• Mol File: 1401863-92-0.mol

Chemical Properties

• CAS DataBase Reference: N-(4-aminobutyl)-1-(4-methoxyphenyl)-9H-β-carboline-3-amide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-aminobutyl)-1-(4-methoxyphenyl)-9H-β-carboline-3-amide(1401863-92-0)
• EPA Substance Registry System: N-(4-aminobutyl)-1-(4-methoxyphenyl)-9H-β-carboline-3-amide(1401863-92-0)

Safety Data

• Hazardous Substances Data: 1401863-92-0(Hazardous Substances Data)

Upstream product

• 82789-20-6 1-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid 
• 68014-36-8 methyl 1-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate 
• 243842-55-9 (3S)-1-(4-methoxyphenyl)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid methyl ester 
• 123-11-5 4-methoxy-benzaldehyde 
• 4299-70-1 L-tryptophan methyl ester 

Downstream Products

• 1401863-95-3 C₂₃H₂₄N₄O₂*ClH 

Relevant articles and documents

Novel β-carboline-based indole-4,7-quinone derivatives as NAD(P)H: Quinone-oxidoreductase-1 inhibitor with potent antitumor activities by inducing reactive oxygen species, apoptosis, and DNA damage

Eighteen new β-carboline-based indole-4,7-quinone derivatives (12a–i and 13a–i) were designed and synthesized, and their in vitro and in vivo antiproliferative activities were studied. Most of target compounds showed strong inhibition on three human tumor cells' proliferation. In particular, the most active compound 13g not only displayed more prominent antiproliferative activities than β-lapachone, a clinical antitumor candidate, but also exerted significant NAD(P)H: quinone-oxidoreductase-1 (NQO1) inhibitory activity and NQO1-dependent cytotoxicity in HT29 cells. Furthermore, 13g dose-dependently induced high ROS levels in HT29 cells, and selectively inhibited cancer cell but not non-tumor colon cell proliferation in vitro. Importantly, 13g promoted HT29 cell apoptosis and DNA damage by regulating relative apoptotic proteins and H2AX expression. Finally, 13g displayed significant growth inhibition of HT29 human colorectal adenocarcinoma xenograft in mice without overt toxicity.

COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME

Present invention refers to new compounds of formula I or II, its synthesis and its use in the treatment of metabolic syndrome, particularly for the treatment of type I or type II diabetes and/or metabolic syndrome or metabolic disease or metabolic disorders.